Arrowhead’s RNAi therapeutic plozasiran shows promise in familial chylomicronaemia syndrome

Arrowhead Pharmaceuticals has announced positive results from a late-stage study of its investigational RNAi therapeutic in patients with familial chylomicronaemia syndrome (FCS), a rare genetic disorder affecting an estimated one to two per million people.